New biosynthetic methods and a recent USP equivalence ruling are driving the move away from Horseshoe Crab blood-derived testing reagents—impacting biodiversity, innovation, and supply chains. Jay Bolden (Eli Lilly), Adele Cheli (GSK), and Ryan Phelan (Revive & Restore) shared their work making this change happen and previewed the new Horseshoe Crab Scorecard.
